多发性骨髓瘤患者生化进展或临床进展后的结局
该回顾性研究纳入1347例复发多发性骨髓瘤患者,其中60.4%为生化进展、39.6%为临床进展。生化进展患者从二线治疗至下次治疗的中位时间及首次复发后的中位总生存均优于临床进展患者。男性、浆细胞标记指数≥2%、诊断时髓外疾病与临床进展风险升高相关,而≥非常好的部分缓解与风险降低相关。
要点
- 复发时60.4%为生化进展,39.6%为临床进展。
- 生化进展者二线治疗至下次治疗中位时间17.0个月,临床进展者9.6个月(P<.001)。
- 生化进展者首次复发后中位总生存59.4个月,临床进展者26.2个月(P<.001)。
核心结论
- 临床进展患者进展后结局劣于生化进展患者。
- 一线治疗缓解更深者发生临床进展的可能性更低。
- 诊断时存在特定CRAB症状预示复发时出现相似CRAB症状。
研究设计与样本
- 回顾性评估1347例复发多发性骨髓瘤患者。
主要发现
- 复发时生化进展占60.4%,临床进展占39.6%。
- 复发时最常见症状为新发或进展性骨病(80.9%)、贫血(38.0%)和肾衰竭(12.7%)。
- 生化进展组从二线治疗至下次治疗中位时间17.0个月 vs 临床进展组9.6个月(P<.001)。
- 生化进展组首次复发后中位总生存59.4个月 vs 临床进展组26.2个月(P<.001)。
- 男性(OR 1.49;95%CI 1.02-2.18;P=.04)、浆细胞标记指数≥2%(OR 1.58;95%CI 1.02-2.45;P=.04)、诊断时髓外疾病(OR 1.84;95%CI 1.08-3.13;P=.03)与临床进展风险升高相关;≥非常好的部分缓解与临床进展风险降低相关(OR 0.62;95%CI 0.43-0.91;P=.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Almost all patients with multiple myeloma (MM) eventually relapse, either asymptomatically or with end-organ damage. However, it remains unclear whether initiating therapy at the time of biochemical progression (BP) improves the outcomes compared with initiating therapy at the clinical progression (CP) stage. Here, we retrospectively assessed 1347 patients with relapsed MM. Most progressions were BP (60.4%); 39.6% had CP. The most prevalent symptoms at relapse were new or evolving bone disease (80.9%), anemia (38.0%), and renal failure (12.7%). Patients with BP had longer median time from second-line treatment to the next treatment compared with patients who had CP (17.0 vs 9.6 months; P < .001) as well as longer median overall survival from first relapse (59.4 vs 26.2 months; P < .001). Male sex (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.02-2.18; P = .04), plasma cell labeling index ≥2% (OR, 1.58; 95% CI, 1.02-2.45; P = .04), and extramedullary disease at diagnosis (OR, 1.84; 95% CI, 1.08-3.13; P = .03) were associated with higher risk of CP, whereas very good partial remission or better had decreased risk of CP (OR, 0.62; 95% CI, 0.43-0.91; P = .02). To conclude, patients with CP have inferior postprogression outcomes compared with patients who have BP. Patients with deeper response to first-line therapy are less likely to develop CP. The presence of a specific CRAB (C, hypercalcemia; R, renal failure; A, anemia; B, bone disease) symptom at diagnosis predicts for the development of similar CRAB symptoms at relapse.
引用
- Goldman-Mazur S, Visram A, Kapoor P, et al. Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Adv. 2023. PMID: 35413102. doi:10.1182/bloodadvances.2022007082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。